Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 279,178 shares, a growth of 44.1% from the November 30th total of 193,734 shares. Based on an average trading volume of 227,031 shares, the short-interest ratio is presently 1.2 days. Approximately 19.9% of the shares of the company are short sold. Approximately 19.9% of the shares of the company are short sold. Based on an average trading volume of 227,031 shares, the short-interest ratio is presently 1.2 days.

Shuttle Pharmaceuticals Price Performance

Shares of SHPH traded down $0.11 on Monday, reaching $1.76. 5,401 shares of the stock traded hands, compared to its average volume of 173,992. The stock’s 50-day moving average price is $2.16 and its 200-day moving average price is $3.20. The firm has a market cap of $2.82 million, a price-to-earnings ratio of -0.15 and a beta of -0.87. Shuttle Pharmaceuticals has a 12 month low of $1.26 and a 12 month high of $25.25.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($1.05) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

An institutional investor recently bought a new position in Shuttle Pharmaceuticals stock. Connective Capital Management LLC bought a new position in shares of Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 100,535 shares of the company’s stock, valued at approximately $357,000. Connective Capital Management LLC owned 9.40% of Shuttle Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 4.58% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SHPH. Weiss Ratings restated a “sell (e)” rating on shares of Shuttle Pharmaceuticals in a research note on Monday, December 15th. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .